Skip to main content
ANAGENICS LIMITED logo

ANAGENICS LIMITED — Investor Relations & Filings

Ticker · AN1 ISIN · AU0000198095 ASX Manufacturing
Open in API
Filings indexed 1,067 across all filing types
Latest filing 2017-08-20 Regulatory Filings
Country AU Australia
Listing ASX AN1

About ANAGENICS LIMITED

https://anagenics.com

Anagenics Limited is a health and wellness company focused on the development and commercialization of science-based anti-aging and longevity solutions. The company specializes in the research and distribution of clinically validated products targeting hair loss and skin health. Its core portfolio includes the évolis brand, which utilizes proprietary FGF5 inhibitor technology to promote hair growth and improve hair health. Through its subsidiaries, such as Advangen and BLC Cosmetics, the company manages a diverse range of premium skincare and wellness brands. Anagenics operates across international markets, providing consumer-facing products and professional-grade treatments backed by scientific research. The company's strategic focus remains on expanding its presence in the global beauty-tech and wellness sectors by leveraging its intellectual property and distribution networks.

Recent filings

Filing Released Lang Actions
CELLMID COMPLETES US CONSUMER STUDY 3 pages 117.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement titled 'CELLMID COMPLETES US CONSUMER STUDY' reporting the completion and results of a consumer study on hair care products. It contains no financial statements, regulatory certifications, or detailed financial data. The content focuses on study results and marketing implications rather than financial performance or management changes. It is a corporate announcement about a product study completion and its implications for marketing and sales. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. Given the nature and length (6639 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2017-08-20 English
CELLMID SECURES PREMIUM US RETAIL CHANNEL FOR EVOLIS 2 pages 78.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Cellmid Limited about securing a premium US retail channel for its product evolis®. It details a new partnership with Neiman Marcus, shipment of the first order, and product distribution plans. The content is a business update about a commercial partnership and product distribution, not a financial report, regulatory filing, or management report. The document length is 4320 characters, which is relatively short and typical for an announcement. There is no financial data, no mention of voting results, no legal proceedings, no executive changes, no earnings data, and no detailed investor presentation. This fits best with a general regulatory announcement or business update. According to the filing definitions, such announcements that do not fit other categories are classified as Regulatory Filings (RNS).
2017-08-02 English
Chinese Import Permits Received 2 pages 83.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Cellmid Limited regarding the receipt of Chinese import permits for their products Jo-Ju® and Lexilis®. It discusses operational updates such as the ability to ship orders and resume negotiations in China. There is no detailed financial data, no comprehensive financial statements, no management discussion of financial results, nor any regulatory filing or certification. The document is a company announcement about a business development event rather than a financial report or regulatory filing. It is relatively short (4428 characters) and focused on a specific operational update. Therefore, it fits best into the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2017-07-31 English
Appendix 4C - quarterly 8 pages 325.5KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'STRONG SALES GROWTH FOR CELLMID IN FY2017' and includes a preliminary sales report and notes to the Appendix 4C for the last quarter of the 2017 financial year. It contains detailed financial data such as cash flows from operating, investing, and financing activities, as well as operational updates and business performance commentary. The presence of the Appendix 4C quarterly report, which is a regulatory requirement for Australian listed entities to report quarterly cash flows and activities, indicates this is a quarterly financial report. The document is about the quarter ended 30 June 2017 and includes substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). FY 2017
2017-07-27 English
Nature Paper MK in Melanoma 4 pages 131.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Cellmid Limited dated 3 July 2017. It discusses the publication of a significant scientific study in the journal Nature validating Cellmid's cancer therapeutic and diagnostic programs targeting midkine. The content focuses on the scientific findings, the significance of the study for the company, and the potential impact on their drug development programs. There are no financial statements, earnings data, management discussion of financial results, or regulatory certifications. The document is a corporate announcement about a scientific publication and its implications, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of a significant scientific publication relevant to the company’s business. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2017-07-02 English
Change of Director's Interest Notice-Halasz 3 pages 279.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, the nature of the transaction (on-market trade), and compliance with closed period trading rules. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial performance data, management discussion, or regulatory filings beyond director dealings. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement or a certification but a formal notice of director share transactions.
2017-06-04 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.